The review articles listed here summarize a substantial amount of work demonstrating that exogenous administration of AnxA1 or Ac2-26 effectively limited or resolved inflammation in mouse models of stroke, myocardial ischemia, non-alcoholic steatohepatitis, rheumatoid arthritis, multiple sclerosis, colitis and asthma. This evidence concerns the gene ANXA1 and stroke disorder.